Paul Glavina Joins Relay Medical and HemoPalm Team as Vice President, In Vitro Diagnostics
February 13, 2019 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), an engine of MedTech innovation, is pleased to announce the appointment of Paul Glavina as Vice President, In Vitro Diagnostics, of Relay Medical Corp.
Paul is a veteran leader of more than 30 years in the application of biosensors at the point of patient care (“Point of Care Testing”, POCT). As Relay’s Vice President, In Vitro Diagnostics (IVDs), he will be responsible for heading the company’s evaluation, development, execution, and exit of innovative IVD technology opportunities, including the ongoing HemoPalm project.
Previously, Paul led the research and product technology teams for a large multinational IVD company, where he was responsible for research to develop new point of care diagnostics as well as technical oversight of all on-market product and manufacturing changes for a market-leading handheld blood gas, coagulation, and immunoassay analyzer product. He has experience in virtually all aspects of the IVD business, including technology assessment and research, product design and development, quality control and quality assurance, marketing, sales, and technical support, as well as regulatory and scientific affairs.
“I am extremely pleased to have Paul join us. His IVD industry expertise and technical knowledge, combined with his extensive relationships and leadership capabilities are very important to the advancement of the HemoPalm product and to the identification and evaluation of other opportunities for Relay.” said Lahav Gil, CEO, Relay Medical Corp.
“I’m excited to be joining Relay’s mission to nurture novel medical technologies and bring them not only to the market, but to clinicians and to the patients who are the ultimate beneficiaries. In particular, I look forward to applying my knowledge and experience to further Relay’s HemoPalm project and guide it to a successful market entry.” said Paul Glavina, Vice President, In Vitro Diagnostics, Relay Medical Corp.
About Paul Glavina
Paul is a technical and business leader with a record of bringing disruptive, world-class in vitro diagnostics products from concept to the marketplace and ensuring continued market growth and expansion. He was a leader for over 25 years with Abbott Point of Care and its precursor, i-STAT Corporation, designing, developing, manufacturing, and marketing the world’s first handheld blood gas and electrolyte analyzer. He is an inventor with a number of patents and an Abbott Chairman’s Award.
Paul has also been a leader in the broader diagnostics technical and professional community, including as a member of United States Technical Advisory Group to ISO TC 212, an advisor and contributing author to multiple Clinical and Laboratory Standards Institute projects, a member of the Laboratory Working Group, National Kidney Disease Education Program, a member of the CLIA Working Group, Advanced Medical Technology Association (AdvaMed), and a member of the Technical Advisory Committee, Canadian Microelectronics Corporation.
About Relay Medical Corp.
Relay Medical is an evolving “Integrated MedTech Accelerator” headquartered in Toronto, Canada, acquiring early-stage technologies and inventions, advancing and preparing them for pre-commercial acquisitions in the HealthTech marketplace. By integrating the funding, development and exit process into one organization led and managed by one expert team, Relay Medical is building the capacity to accelerate and transact technologies with high efficiency and grow into a leading engine for MedTech innovation in the global HealthTech marketplace.
W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
EU Investor Relations
Office. +49 (0) 177 774 2314
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the HemoPalm product described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com